Federal contractor · MILFORD, DE

INSTANOSIS INC

No contract obligations recorded for INSTANOSIS INC in FY2026. Since FY2022: $50K. It also received $3.6M in federal grants and other assistance in FY2026.

Obligations · FY2026
$0
New awards
0
Sole-source
—
Single offer
—
UEI
CA5GQKREPCE4
Small businessWoman-owned
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 747.7KFY2022
  2. -697.7KFY2023

Top buying agencies

Obligations in FY2026.

No contract obligations recorded for INSTANOSIS INC in FY2026.

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

INSTANOSIS INC received $3.6M in federal assistance in FY2026, on 3 actions (0 new awards), −12% vs FY2025. Its largest program was 93.279 · Drug Use and Addiction Research Programs ($3.6M).

Assistance · FY2026
$3.6M
New awards
0
Actions
3
Since FY2022
$9.1M

Assistance by fiscal year

  1. 598.2KFY2022
  2. 149.8KFY2023
  3. 733.8KFY2024
  4. 4.1MFY2025
  5. 3.6MFY2026

By type

  1. Grants$3.6M100%

Top programs

  1. 93.279 · Drug Use and Addiction Research Programs$3.6M100%

Awarding agencies

  1. National Institutes of Health$3.6M100%
    Department of Health and Human Services

Largest awards

  1. RAPID, INSTRUMENT-FREE AND HIGH SENSITIVITY OVER-THE-COUNTER URINE FENTANYL TESTING - PROJECT SUMMARY FENTANYL IS THE LEADING CAUSE OF…$3.3M
    93.279 · Drug Use and Addiction Research Programs· National Institutes of Health· Project grant· Mar 8, 2024 – May 12, 2026· R44DA060647
  2. A RAPID, SENSITIVE AND INSTRUMENT-FREE ORAL FLUID FENTANYL TEST - PROJECT SUMMARY FENTANYL IS A MAJOR CONTRIBUTOR TO THE OPIOID EPIDEMIC…$3M
    93.279 · Drug Use and Addiction Research Programs· National Institutes of Health· Project grant· Jun 6, 2025 – May 22, 2026· R44DA061963
  3. ADDRESSING EMERGING DRUG THREATS WITH INSTASTRIP RAPID TESTS - XYLAZINE IS A SYNTHETIC NON-OPIOID ALPHA2-ADRENERGIC AGONIST THAT HAS…$2M
    93.279 · Drug Use and Addiction Research Programs· National Institutes of Health· Cooperative agreement· Mar 8, 2024 – May 18, 2026· U44DA060264

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 8, 2026, loaded Oct 8, 2026 · FY2022–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 7, 2026, loaded Oct 7, 2026.